|Bid||5.51 x 800|
|Ask||0.00 x 1100|
|Day's Range||6.07 - 6.89|
|52 Week Range||4.85 - 25.20|
|Beta (3Y Monthly)||1.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.00|
If you want to know who really controls Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), then you'll have to look at the...
Strong Quarter-Over-Quarter Performance 26% Increase in U.S. Product Revenue46% Increase in Dermatology Revenue23% Reduction in Operating Expenses PETALUMA, Calif., Aug..
Sonoma Pharmaceuticals, Inc. (SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies to millions of patients living with chronic skin conditions, today announced that it received a formal determination letter from Nasdaq notifying the company that it is now compliant with the minimum bid price requirement for continued listing on the Nasdaq Capital Market® and is no longer subject to delisting at this time. As announced previously, on January 4, 2019, Sonoma received a letter from Nasdaq, indicating that it did not comply with the $1.00 minimum closing bid price requirement for its common stock for continued listing on the Nasdaq Capital Market. Nasdaq granted the company a compliance period of 180 calendar days, or until July 3, 2019, to regain compliance with the listing rule.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 8) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Inspire ...
Strong Annual Year-Over-Year Growth with 14% Revenue Growth Strong Quarter-Over-Quarter Growth with 20% Revenue Growth and 25% Reduction in Expenses Reduction in Annual.
Specialty pharmaceutical company Sonoma Pharmaceuticals, Inc. (SNOA), today announced the timing for a 1-for-9 reverse split of its outstanding common stock which will be effected on June 19, 2019 at 5:00 pm EDT. Sonoma common stock will begin trading on The Nasdaq Capital Market on a 1-for-9 adjusted basis when the market opens on June 20, 2019. The reverse stock split was previously approved by the Company’s stockholders at the Company’s Special Meeting held on May 30 and June 11, 2019.
Specialty pharmaceutical company Sonoma Pharmaceuticals, Inc. (SNOA), today announced the sale of certain animal health product rights and assets for the Asian and European markets to Petagon, Limited, an international importer and distributor of quality pet food and products, for $2.7 million. Petagon has been a distributor of our Microcyn®AH products in the Chinese, Hong Kong and other Asian markets for the past 5 years. The sale involves certain Asian patents and trademarks and the exclusive right to distribute animal health care products in Asia and Europe.
While not a mind-blowing move, it is good to see that the Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) share price has gained 16% in the last three months. But that doesn't change the fact that the returns over the last half dec...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 12) Elanco Animal Health Inc (NYSE: ELAN ) CareDx Inc ...
The measures come on the heels of Sonoma’s highest revenue quarter ended December 31, 2018. The company reported a net loss of $2.3 million during the quarter ended December 31, 2018 compared to $3.2 million for the quarter ended December 31, 2017. The company continually evaluates and reduces expenses including the current reductions in its workforce.
CEO Jim Schutz and CFO Robert Miller Step DownFrederick (Bubba) Sandford Appointed as New CEO and Interim CFO and will Join the Board PETALUMA, Calif., Dec. 14, 2018 -- Sonoma.
If you own shares in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Sonoma Pharmaceuticals, Inc. (SNOA) today announced the pricing of a “best efforts” public offering of units consisting of one share of common stock, together with one half of one warrant to purchase one share of common stock at an exercise price equal to $1.00 per whole share. The public offering price was $1.00 per unit. Certain investors, who would beneficially own, together with its affiliates and certain related parties, more than 4.99% of the outstanding common stock as a result of the public offering, can purchase series C convertible preferred stock convertible into shares of common stock, in lieu of purchasing common stock.
NEW YORK, NY / ACCESSWIRE / November 16, 2018 / Pharmaceutical companies Arena Pharmaceuticals and Sonoma Pharmaceuticals were in the green on Thursday. While Sonoma did not have any news to note, Arena Pharmaceuticals announced that it has entered into a lucrative licensing agreement with United Therapeutics. Arena Pharmaceuticals, Inc. shares were up 22.62% yesterday on around 4.7 million shares traded.
• Total Revenue of $4.9 Million, up 13% over June 2018 Quarter• Total Revenue up 14% over September 2017 Quarter Conference Call Begins at 4:30 pm EST Today PETALUMA, Calif.,.
Sonoma Pharmaceuticals, Inc. (SNOA) today announced that financial results for its fiscal year 2019 second quarter, ended September 30, 2018, will be released after the U.S. markets close on November 8, 2018. The earnings release will be followed by a conference call at 1:30 p.m. PST on November 8, 2018, to discuss fiscal second quarter results. Individuals interested in participating in the conference call may do so by dialing 877-303-7607 for domestic callers or 973-638-3203 for international callers. Those interested in listening to the conference call live via the internet may do so at https://edge.media-server.com/m6/p/b5tvh3bj. A telephone replay will be available for seven days following the conclusion of the call by dialing 855-859-2056 for domestic callers, or 404-537-3406 for international callers, and entering conference code 3686329.
A look at the shareholders of Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, Read More...